Quick summary
Bortezomib (Velcade) is the first-in-class proteasome inhibitor that revolutionized multiple myeloma treatment. FDA-approved since 2003, it remains a cornerstone of frontline and relapsed therapy, though peripheral neuropathy is the principal dose-limiting toxicity.
Overview
Bortezomib (Velcade) is an FDA-approved first-in-class dipeptide boronic acid proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. Approved in 2003, it revolutionized myeloma treatment and remains a cornerstone of frontline and relapsed therapy regimens worldwide, typically used in combination with lenalidomide and dexamethasone.
Mechanism of action
Bortezomib is a dipeptide boronate that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. The boronic acid moiety forms a reversible covalent bond with the N-terminal threonine residue of the 20S proteasome beta5 subunit, blocking protein degradation. This causes accumulation of pro-apoptotic proteins normally targeted for proteasomal destruction, including IκB (which sequesters the NF-κB transcription factor). NF-κB inhibition is particularly relevant in myeloma, where constitutive NF-κB activity drives proliferation and survival. Additionally, bortezomib phosphorylates Bcl-2, upregulates the BH3-only protein NOXA, blocks p53 degradation, activates caspase cascades, generates reactive oxygen species, and inhibits tumor angiogenesis. The combined pro-apoptotic burden overwhelms the unfolded protein response in malignant plasma cells.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| multiple myeloma (combination or monotherapy) | intravenous | 1.3–1.3 mg/m² | Days 1, 4, 8, 11 of 21-day cycle (or weekly schedules) | Standard dose 1.3 mg/m² IV bolus. Cycles vary by regimen. Reduce dose for Grade 3+ neuropathy. Antiviral prophylaxis recommended to prevent herpes zoster reactivation. |
| multiple myeloma (subcutaneous, reduced neuropathy) | subcutaneous | 1.3–1.3 mg/m² | Days 1, 4, 8, 11 of 21-day cycle | Subcutaneous injection preferred when neuropathy is a concern. Equivalent efficacy to IV with approximately 50% reduction in peripheral neuropathy incidence. Rotate injection sites. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Bortezomib received accelerated FDA approval in May 2003 for relapsed/refractory multiple myeloma based on the SUMMIT Phase II trial, which showed a 35% response rate in heavily pretreated patients. Full approval followed in 2005 after APEX confirmed superiority over high-dose dexamethasone (38% vs. 18% response rate). The VISTA trial established bortezomib + melphalan + prednisone as a frontline standard. Approval for mantle cell lymphoma followed in 2006. Peripheral neuropathy remains the principal dose-limiting toxicity; subcutaneous administration reduces neuropathy incidence compared to intravenous delivery.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Bortezomib for synergistic effects.
Legal status
FDA-approved since 2003 for multiple myeloma and since 2006 for mantle cell lymphoma. Available as lyophilized powder for intravenous or subcutaneous injection. Not a controlled substance. Generic bortezomib available since 2016.
Sourcing & access
Prescription required
Bortezomib is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Bortezomib (Velcade) is a dipeptide boronic acid proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma. Approved in 2003, it was the first drug in its class and remains a cornerstone of myeloma treatment worldwide.
Bortezomib reversibly inhibits the 26S proteasome, causing accumulation of pro-apoptotic proteins and inhibition of NF-kB signaling, which is constitutively active in myeloma cells. This combined pro-apoptotic burden overwhelms the survival mechanisms of malignant plasma cells.
Peripheral neuropathy is the dose-limiting toxicity, presenting as numbness, tingling, and pain in the extremities. Subcutaneous administration reduces neuropathy incidence by approximately 50 percent compared to intravenous delivery. Antiviral prophylaxis is also recommended to prevent herpes zoster reactivation.
Both routes are approved at 1.3 mg/m2 on Days 1, 4, 8, and 11 of 21-day cycles. Subcutaneous injection is preferred when neuropathy is a concern due to equivalent efficacy with significantly less neuropathy. Injection sites should be rotated.
Yes, generic bortezomib has been available since 2016 following expiration of the original Velcade patent. It is supplied as a lyophilized powder for reconstitution and can be administered by either intravenous bolus or subcutaneous injection. The subcutaneous formulation is commonly preferred when peripheral neuropathy is a concern because it produces equivalent efficacy with roughly half the neuropathy incidence.
Research references
- Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPubMed
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPubMed
- Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trialPubMed
- Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPubMed
- Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsPubMed